Publications by authors named "Denis C Talbot"

Claim this Profile
I
Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013-2015.
Tracey S E Genus, Catherine Bouvier, Kwok F Wong, Rajaventhan Srirajaskanthan, Brian A Rous, Denis C Talbot

Br J Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
Daniel Morgensztern, Manuel Cobo, Santiago Ponce Aix, Pieter E Postmus, Conrad R Lewanski, Denis C Talbot

Cancer· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis.
Pamela J Kaisaki, Anthony Cutts, Niko Popitsch, Carme Camps, Melissa M Pentony, Denis C Talbot

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ocular Toxicity of Mitogen-Activated Protein Kinase Inhibitors.
Robert M J Purbrick, Olaoluwakitan A Osunkunle, Denis C Talbot, Susan M Downes

JAMA Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.
Anna C Bibby, Selina Tsim, Nikolaos Kanellakis, Hannah Ball, Denis C Talbot

Eur Respir Rev· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinoma.
Sarah Ew Briggs, Paul Gozzard, Denis C Talbot

Immunotargets Ther· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.
Tim Meyer, Wendi Qian, Martyn E Caplin, Graham Armstrong, Si-Houy Lao-Sirieix, Denis C Talbot

Eur J Cancer· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
Mary E R O'Brien, Rabab M Gaafar, Sanjay Popat, Francesco Grossi, Allan Price, Denis C Talbot

Eur J Cancer· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In reply: response to Marioni.
David N Church, Denis C Talbot

Curr Oncol Rep· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Suresh S Ramalingam, Fiona Blackhall, Maciej Krzakowski, Carlos H Barrios, Keunchil Park, Denis C Talbot

J Clin Oncol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative analysis of survivin protein expression and its therapeutic depletion by an antisense oligonucleotide in human lung tumors.
Anna L Olsen, Joanne M Davies, Louise Medley, David Breen, Denis C Talbot

Mol Ther Nucleic Acids· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survivin in solid tumors: rationale for development of inhibitors.
David N Church, Denis C Talbot

Curr Oncol Rep· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients.
Azeem Saleem, Julian C Matthews, Malcolm Ranson, Sophie Callies, Valérie André, Denis C Talbot

Theranostics· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma.
William G Herrington, Denis C Talbot, Michael M Lahn, John T Brandt, Sophie Callies

Am J Kidney Dis· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions.
Valerie Jenkins, Ivonne Solis-Trapala, Carolyn Langridge, Susan Catt, Denis C Talbot

J Clin Oncol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study.
Denis C Talbot, Malcolm Ranson, Joanna Davies, Michael Lahn, Sophie Callies

Clin Cancer Res· December 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of vinflunine in malignant pleural mesothelioma.
Denis C Talbot, Jacques Margery, Gérard Dabouis, Graham Dark, Henry Taylor

J Clin Oncol· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.
Denis C Talbot, Joachim von Pawel, Emma Cattell, S Murray Yule, Claire Johnston

Clin Cancer Res· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isolation of a small molecule inhibitor of DNA base excision repair.
Srinivasan Madhusudan, Fiona Smart, Paul Shrimpton, Jason L Parsons, Laurence Gardiner, Denis C Talbot

Nucleic Acids Res· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.
Jeremy P Braybrooke, Andrew Slade, Gael Deplanque, Richard Harrop, Srinivasan Madhusudan, Denis C Talbot

Clin Cancer Res· February 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
Srinivasan Madhusudan, Martin Foster, Sethupathi R Muthuramalingam, Jeremy P Braybrooke, Susan Wilner, Denis C Talbot

Clin Cancer Res· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.
Jeremy P Braybrooke, Nicola C Levitt, Simon Joel, Theresa Davis, Srinivasan Madhusudan, Denis C Talbot

Clin Cancer Res· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.
David J Propper, David Chao, Jeremy P Braybrooke, Pru Bahl, Parames Thavasu, Denis C Talbot

Clin Cancer Res· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis